FDA authority to suspend trials barring women of childbearing potential recommended by AIDS task force.
FDA AUTHORITY TO HALT TRIALS EXCLUDING WOMEN PROPOSED in a draft recommendation by the National Task Force on AIDS Drug Development at its Jan. 19 meeting. FDA regs would be amended to provide the agency with the authority to place a clinical hold on trials involving drugs for life-threatening diseases if the sponsor is determined to be excluding women when there is no evidence of reproductive toxicity. If the exclusion continued, FDA would have the authority to terminate the sponsor's IND.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth